LLY

1,018.6

+3.3%↑

JNJ

229.93

+0.53%↑

ABBV

213.62

+1.94%↑

UNH

389.29

-0.09%↓

AZN

184.71

+0.4%↑

LLY

1,018.6

+3.3%↑

JNJ

229.93

+0.53%↑

ABBV

213.62

+1.94%↑

UNH

389.29

-0.09%↓

AZN

184.71

+0.4%↑

LLY

1,018.6

+3.3%↑

JNJ

229.93

+0.53%↑

ABBV

213.62

+1.94%↑

UNH

389.29

-0.09%↓

AZN

184.71

+0.4%↑

LLY

1,018.6

+3.3%↑

JNJ

229.93

+0.53%↑

ABBV

213.62

+1.94%↑

UNH

389.29

-0.09%↓

AZN

184.71

+0.4%↑

LLY

1,018.6

+3.3%↑

JNJ

229.93

+0.53%↑

ABBV

213.62

+1.94%↑

UNH

389.29

-0.09%↓

AZN

184.71

+0.4%↑

Home・Elenco Azioni・Roivant Sciences Ltd

Roivant Sciences Ltd

Chiusa

SettoreSettore sanitario

28.21 -1.19

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

27.82

Massimo

28.7

Metriche Chiave
By Trading Economics
Entrata	-200M -314M
Vendite	428K 2M
Margine di Profitto	-15,692.896
Dipendenti	750
EBITDA	-132M -290M

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+20.55% upside

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	4.9B 20B
Apertura precedente	29.4
Chiusura precedente	28.21

Notizie sul Sentiment di mercato

By Acuity

50%

174 / 345 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Weak Bullish Evidence

11 / 11.18 Supporto e resistenza

Roivant Sciences Ltd Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

19 mag 2026, 20:36 UTC

Acquisizioni, Fusioni, Takeovers

Analog Devices to Buy Empower Semiconductor for $1.5 Billion

19 mag 2026, 23:47 UTC

Discorsi di Mercato

Nikkei May Decline as Concerns About Energy, Material Costs Persists -- Market Talk

19 mag 2026, 23:34 UTC

Discorsi di Mercato

Gold Edges Higher on Possible Technical Recovery -- Market Talk

19 mag 2026, 23:28 UTC

Discorsi di Mercato

Utili

Global Forex and Fixed Income Roundup: Market Talk

19 mag 2026, 23:28 UTC

Discorsi di Mercato

Utili

F&P Healthcare's Outlook Key for Investors -- Market Talk

19 mag 2026, 23:10 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

19 mag 2026, 23:10 UTC

Discorsi di Mercato

Kiwi Property's Dividend Growth Reliant on Several Factors -- Market Talk

19 mag 2026, 22:02 UTC

Utili

ZTO Express (Cayman): Di Xu to Resign From Board

19 mag 2026, 22:01 UTC

Utili

ZTO Express (Cayman) 1Q Adj EPS 43c >ZTO

19 mag 2026, 22:01 UTC

Utili

ZTO Express (Cayman) 1Q EPS 39c >ZTO

19 mag 2026, 22:00 UTC

Utili

ZTO Express (Cayman) 1Q Rev $1.93B >ZTO

19 mag 2026, 21:37 UTC

Utili

Cracks Are Starting to Appear in the Chip Stock Rally -- Barrons.com

19 mag 2026, 21:31 UTC

Acquisizioni, Fusioni, Takeovers

How NextEra Can Fix Dominion's Strange AI Problem -- Barrons.com

19 mag 2026, 21:01 UTC

Utili

Home Depot Beats Earnings Estimates as Shoppers Defy Inflation Fears. The Stock Advances. -- Barrons.com

19 mag 2026, 20:58 UTC

Utili

These Stocks Are Today's Movers: CoreWeave, Nvidia, Home Depot, Akamai, Agilysys, Micron, and More -- Barrons.com

19 mag 2026, 20:46 UTC

Azioni calde

Stocks to Watch Recap: ServiceNow, Home Depot, CoreWeave -- WSJ

19 mag 2026, 20:43 UTC

Discorsi di Mercato

Canada 30-Year Yield Hits Highest Level Since 2010 -- Market Talk

19 mag 2026, 20:34 UTC

Utili

James Hardie Industries Sees FY27 Sales $5.25B-$5.41B >JHX

19 mag 2026, 20:32 UTC

Utili

James Hardie Industries: Targeting Pro Forma Adjusted EBITDA Growth of 4% to 8% in FY27 >JHX

19 mag 2026, 20:32 UTC

Utili

James Hardie Industries 4Q EPS 5c >JHX

19 mag 2026, 20:32 UTC

Utili

James Hardie Industries 4Q Sales $1.4B >JHX

19 mag 2026, 20:21 UTC

Acquisizioni, Fusioni, Takeovers

Analog Devices to Buy Empower Semiconductor for $1.5B

19 mag 2026, 20:18 UTC

Discorsi di Mercato

Canada CPI Data Has Accounting Quirk Related to Travel Tours -- Market Talk

19 mag 2026, 20:13 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

19 mag 2026, 20:13 UTC

Discorsi di Mercato

'Hard to Square' Canada Rate Hikes Expectations Given Mild Core -- Market Talk

19 mag 2026, 20:03 UTC

Acquisizioni, Fusioni, Takeovers

Analog Devices: Deal Further Advances Position as Strategic, System-Level Grid-To-Core Power Partner for Hyperscalers, AI Silicon Developers >ADI

19 mag 2026, 20:03 UTC

Acquisizioni, Fusioni, Takeovers

Analog Devices: Phillips Will Continue Leading IVR Technology Efforts as Part of ADI >ADI

19 mag 2026, 20:02 UTC

Acquisizioni, Fusioni, Takeovers

Analog Devices Will Acquire Empower in All-Cash Transaction for $1.5 B >ADI

19 mag 2026, 20:02 UTC

Acquisizioni, Fusioni, Takeovers

Analog Devices to Acquire Empower Semiconductor, Expanding Its Next-Generation High-Density Power Portfolio for the AI Era

19 mag 2026, 19:23 UTC

Discorsi di Mercato

Oil Futures Slip With Market Back on U.S.-Iran Deal Watch -- Market Talk

Confronto tra pari

Modifica del prezzo

Roivant Sciences Ltd Previsione

Obiettivo di Prezzo

By TipRanks

20.55% in crescita

Previsioni per 12 mesi

Media 35.31 USD 20.55%

Alto 41 USD

Basso 29.5 USD

Basato su 8 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Roivant Sciences Ltd - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

8 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 8 che hanno fornito valutazioni azionarie a Roivant Sciences Ltd - Dist negli ultimi 3 mesi.

Punteggio Tecnico

By Trading Central

11 / 11.18Supporto e resistenza

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

There is one bearish event.

Sentiment

By Acuity

174 / 345 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Roivant Sciences Ltd

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It offers VTAMA, a novel topical approved for the treatment of psoriasis and in development for the treatment of atopic dermatitis; IMVT-1402 and batoclimab, which are fully human monoclonal antibodies that targets the neonatal Fc receptor in development across various IgG-mediated autoimmune indications; brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis and non-infectious uveitis, as well as for other therapies in various stages of clinical development; and Namilumab, a fully human anti-GM-CSF monoclonal antibody under Phase 2 clinical trial for the treatment of inflammatory and autoimmune diseases. The company also provides delivery platforms comprising lipid nanoparticle platform and ligand conjugate platform. It has collaboration and license agreements with Boehringer Ingelheim International, GmbH for conducting discovery work on RNA-specific adenosine deaminase 1 targeting and modulating compounds; and with Japan Tobacco Inc. for the rights to develop, register, and market tapinarof in Japan for the treatment of psoriasis and atopic dermatitis. The company was founded in 2014 and is based in London, the United Kingdom.